risk factors involved in biphosphonate-related osteonecrosis of maxillary bones
Clicks: 148
ID: 254129
2011
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.6
/100
12 views
12 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Biphosphonates are used in the treatment of bone
metastases of some cancer forms, such as multiple myeloma,
Paget disease, osteoporosis, fibrous displasia, etc.
A significant consequence of the utilization of such drugs
is osteonecrosis of the maxillary bones. The aim of the
study was to evaluate the risk factors provoking osteonecrosis
of the maxillary bones after the treatment with
biphosphonates, in the patients who addressed the Clinics
of Oral and Maxillo-Facial Surgery between 2006-2011.
Materials and method: 33 patients suffering from this
pathology were registered, their files including information
on age, sex, social background, the disease for which
the drug had been recommended and the prescribed dose,
the manner of its administration and the duration, the
cause of the maxillary lesion, the symptomatology demonstrated
during the first consultation, additional examinations,
treatment and evolution. Results: most cases of
osteo-necrosis had been caused by dental extractions, especially
at the mandible. The higher risk was faced by
women who were administered the drug intravenously.
Conclusions: Post-surgical evolution was favourably influenced
when the surgery had in view the value of the
carboxy-terminal group from the structure of serum
colagen.
| Reference Key |
geletu2011internationalrisk
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Gabriela Geletu;G. Melian;V. Costan;M. L. Ciofu;Eugenia Popescu |
| Journal | acs division of fuel chemistry, preprints |
| Year | 2011 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.